Mylan Launches Three Generic HIV Drugs in Canada

Mylan Pharmaceuticals ULC, a subsidiary of Mylan N.V. (NASDAQ:MYL), announced the launch of three generic products in Canada for the treatment of HIV.

As quoted in the press release:

One of the products is Mylan-Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg, a generic alternative to Truvada®.

Mylan received final approval from Health Canada for this product and for Mylan-Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate 600 mg, 200 mg, and 300 mg, a generic alternative to Atripla®; and Mylan-Tenofovir Disoproxil 300 mg, a generic alternative to Viread®.

Mylan’s Chief Commercial Officer Tony Mauro said, “Mylan has a strong and sustained commitment to expanding access to treatment for HIV/AIDS and other diseases around the world, and today marks another milestone in those efforts. More than 40% of people worldwide being treated for HIV/AIDS with an antiretroviral depend on a Mylan product every day, and we’re proud to further expand access to such medicines in Canada.”

Click here to read the full press release.

Get the Latest Pharmaceutical Investing Stock Information

Get the latest information about companies associated with Pharmaceutical Investing delivered directly to your inbox.


By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.


Leave a Reply